Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride

– Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk – With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile of Tradjenta RIDGEFIELD,...